EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 161 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $40,000 | 0.0% | 803 | -89.4% | 0.00% | 0.0% |
Q4 2019 | $40,000 | +300.0% | 7,600 | +3700.0% | 0.00% | +100.0% |
Q1 2019 | $10,000 | +25.0% | 200 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $8,000 | -87.3% | 200 | -98.9% | 0.00% | -75.0% |
Q3 2018 | $63,000 | -63.6% | 18,100 | -42.4% | 0.00% | -71.4% |
Q2 2018 | $173,000 | +652.2% | 31,400 | +368.7% | 0.01% | +600.0% |
Q1 2018 | $23,000 | +76.9% | 6,700 | +4.7% | 0.00% | – |
Q4 2017 | $13,000 | -95.2% | 6,400 | -61.6% | 0.00% | -100.0% |
Q3 2017 | $269,000 | +20.1% | 16,661 | -8.4% | 0.01% | +25.0% |
Q2 2017 | $224,000 | +121.8% | 18,182 | +5.7% | 0.01% | +100.0% |
Q1 2017 | $101,000 | -76.2% | 17,200 | -58.5% | 0.00% | -75.0% |
Q4 2016 | $424,000 | +40.4% | 41,444 | -8.9% | 0.02% | +23.1% |
Q3 2016 | $302,000 | -31.2% | 45,500 | -45.6% | 0.01% | -43.5% |
Q2 2016 | $439,000 | -60.4% | 83,649 | -41.4% | 0.02% | -68.5% |
Q1 2016 | $1,108,000 | +188.5% | 142,702 | +518.6% | 0.07% | +247.6% |
Q4 2015 | $384,000 | – | 23,069 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |